Additional evidence for TRPV4 involvement was obtained by showing that the severity of the inflammatory fibrosis was attenuated to a similar extent following systemic daily administration of a TRPV4 antagonist, HC-067047, for 20 days. Here, TRPV4 is linked to fibrosis.